Source - RNS
RNS Number : 0412K
hVIVO plc
06 April 2018

For immediate release 7.00am: 6 April 2018



("hVIVO" or the "Company")


Notice of Preliminary Results


hVIVO plc (AIM: HVO) will announce its audited preliminary results for the year ended 31 December 2017 on Thursday, 19 April 2018.



For further information please contact:


hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+1 919 710 9658

Susan Flood

Numis Securities Limited

 +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

FTI Consulting

Simon Conway / Victoria Foster Mitchell (UK)

+44 203 727 1000



Notes to Editors:


About hVIVO plc

hVIVO plc ("hVIVO") is developing a pioneering human-based analytical platform to accelerate drug discovery and development in airways diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS
The company news service from the London Stock Exchange